Payment overview · 2025
General Payments
$241.75
2 reported records · 2 companies
Healthcare provider profile · identity verified
Joshua Ellison, MD
Allopathic & Osteopathic Physicians|Family Medicine · SPRINGFIELD, IL · NPI 1972716033
Verified facts
What the public records show
CMS Open Payments records show Joshua Ellison, MD received $241.75 in general payments during 2025 across 2 reported records.
AstraZeneca Pharmaceuticals LP accounted for 50.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $121.72 | 50.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $120.03 | 49.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $241.75 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.72 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $120.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
41 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
227 | 46 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 652 | 175 |
| Lisinopril | Lisinopril | 439 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 426 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 351 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 341 | 78 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 333 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 302 | 67 |
| Losartan Potassium | Losartan Potassium | 257 | 70 |
| Eliquis | Apixaban | 227 | 46 |
| Omeprazole | Omeprazole | 226 | 64 |
| Gabapentin | Gabapentin | 217 | 56 |
| Metformin Hcl | Metformin Hcl | 187 | 53 |
| Furosemide | Furosemide | 180 | 49 |
| Simvastatin | Simvastatin | 173 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 172 | 31 |
| Sertraline Hcl | Sertraline Hcl | 166 | 41 |
| Famotidine | Famotidine | 159 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 41 |
| Allopurinol | Allopurinol | 154 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 42 |
| Warfarin Sodium | Warfarin Sodium | 128 | 21 |
| Meloxicam | Meloxicam | 126 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 29 |
| Alendronate Sodium | Alendronate Sodium | 109 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 29 |
| Potassium Chloride | Potassium Chloride | 106 | 29 |
| Lovastatin | Lovastatin | 105 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 19 |
| Pregabalin | Pregabalin | 100 | 23 |
| Trazodone Hcl | Trazodone Hcl | 99 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 28 |
| Carvedilol | Carvedilol | 92 | 20 |
| Trulicity | Dulaglutide | 90 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 21 |
| Tramadol Hcl | Tramadol Hcl | 81 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 22 |
| Alprazolam | Alprazolam | 79 | 16 |
| Jardiance | Empagliflozin | 76 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 74 | 23 |
| Montelukast Sodium | Montelukast Sodium | 72 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 70 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 66 | 44 |
| Spironolactone | Spironolactone | 66 | 16 |
| Baclofen | Baclofen | 65 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 58 | 12 |
| Glipizide Er | Glipizide | 57 | 16 |
| Farxiga | Dapagliflozin Propanediol | 54 | suppressed |
| Glipizide | Glipizide | 53 | 15 |
| Lorazepam | Lorazepam | 53 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 12 |
| Atenolol | Atenolol | 48 | 17 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Levetiracetam | Levetiracetam | 47 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 44 | 16 |
| Bupropion Xl | Bupropion Hcl | 43 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 43 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 41 | 41 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Cephalexin | Cephalexin | 36 | 26 |
| Valacyclovir | Valacyclovir Hcl | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 29 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 16 |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Nystatin | Nystatin | 24 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Naproxen | Naproxen | 23 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 17 |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 14 | 14 |
| Finasteride | Finasteride | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lamotrigine Er | Lamotrigine | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $241.75 · 2 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, NURTEC ODT | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error